Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Albireo AB currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 3 distinct art units, suggesting that the company's research and development efforts touch upon several different specialized fields within the life sciences. The prosecution is handled by 6 distinct examiners, which indicates a high degree of diversification in the review process.
The busiest examiner for this portfolio is O DELL, DAVID K, who is responsible for 1 pending office action. Since the workload is spread evenly, no single individual manages more than one case. This distribution across 3 distinct art units means that practitioners must be prepared to address a variety of technical standards and examiner preferences. The lack of examiner concentration suggests that each of the pending office actions will likely follow an independent prosecution path. This structure reduces the risk that a single difficult examiner could negatively impact the entire portfolio, but it also requires coordination to maintain consistency across multiple filings.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| PALENIK, JEFFREY T | 1 | 53.6% | +27.2% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| BARSKY, JARED | 1 | 50.2% | +22.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18207996 | TREATING HEPATITIS | SZNAIDMAN, MARCOS L | 53d |
| 18347233 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18138375 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | BARSKY, JARED | 33d |
| 18207996 | TREATING HEPATITIS | SZNAIDMAN, MARCOS L | 53d |
| 18896264 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | O DELL, DAVID K | — |
| 18778225 | Crystal Modifications of Odevixibat | COLEMAN, BRENDA LIBBY | — |
| 18501402 | Treating Alagille Syndrome (ALGS) | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1615 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18896264 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | O DELL, DAVID K | — | DP | Non-Final OA | — | Pending | Sep 25, 2024 |
| 18778225 | Crystal Modifications of Odevixibat | COLEMAN, BRENDA LIBBY | — | §112DP | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18501402 | Treating Alagille Syndrome (ALGS) | PALENIK, JEFFREY T | 1615 | §103DP | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18347233 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | DEKARSKE, MADELINE MCGUIRE | 1622 | §103Other | Final Rejection | — | Pending | Jul 05, 2023 |
| 18207996 | TREATING HEPATITIS | SZNAIDMAN, MARCOS L | 1628 | §102§103Other | Non-Final OA | 53d | Pending | Jun 09, 2023 |
| 18138375 | SUBCUTANEOUS ADMINISTRATION OF AN ASBT INHIBITOR | BARSKY, JARED | 1628 | §103DP | Non-Final OA | 33d | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial